| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $2,950,544 ) |
| | 2024 | 2024 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R44AI176894 | 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | 000 | 2 | NIH | 3/27/2024 | $953,477 |
| | 2024 | 2024 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R44AI172437 | Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | 000 | 3 | NIH | 6/28/2024 | $997,867 |
| | 2024 | 2024 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R44CA285207 | 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | 001 | 2 | NIH | 7/30/2024 | $999,200 |
| | 2024 | 2023 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R44CA285207 | 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | 000 | 1 | NIH | 3/7/2024 | $0 |
| | 2024 | 2021 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R42HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 3 | NIH | 12/6/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,925,291 ) |
| | 2023 | 2023 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44AI172437 | Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | 000 | 2 | NIH | 6/26/2023 | $997,867 |
| | 2023 | 2023 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44AI176894 | 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | 000 | 1 | NIH | 4/25/2023 | $928,224 |
| | 2023 | 2023 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44CA285207 | 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | 000 | 1 | NIH | 9/19/2023 | $999,200 |
| | 2023 | 2021 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R44CA250646 | Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | 000 | 2 | NIH | 8/15/2023 | $0 |
| | 2023 | 2021 | 7 HILLS PHARMA INC | 2450 HOLCOMBE BLVD STE J | HOUSTON | TX | 77021-2041 | HARRIS | USA | R43AI162169 | Integrin Activation to Augment SARS-CoV-2 Vaccination | 000 | 1 | NIH | 9/27/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $999,300 ) |
| | 2022 | 2022 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44AI172437 | Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | 000 | 1 | NIH | 7/13/2022 | $999,300 |
|
| Issue Date FY: 2021 ( Subtotal = $2,242,256 ) |
| | 2021 | 2021 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R43AI162169 | Integrin Activation to Augment SARS-CoV-2 Vaccination | 000 | 1 | NIH | 4/30/2021 | $297,724 |
| | 2021 | 2021 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44CA250646 | Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | 000 | 2 | NIH | 8/12/2021 | $1,015,591 |
| | 2021 | 2021 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R42HL129612 | A small molecule integrin activator to enhance cord blood transplant | 001 | 3 | NIH | 2/17/2021 | $928,941 |
| | 2021 | 2020 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R42HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 2 | NIH | 10/26/2020 | $0 |
| | 2021 | 2019 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R42CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 000 | 3 | NIH | 6/4/2021 | $0 |
| | 2021 | 2019 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R41AI145507 | Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies | 000 | 1 | NIH | 6/15/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,920,366 ) |
| | 2020 | 2020 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R44CA250646 | Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | 000 | 1 | NIH | 9/11/2020 | $984,409 |
| | 2020 | 2020 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R42HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 2 | NIH | 3/7/2020 | $935,957 |
|
| Issue Date FY: 2019 ( Subtotal = $1,245,180 ) |
| | 2019 | 2019 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R42CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 001 | 3 | NIH | 3/29/2019 | $1,001,898 |
| | 2019 | 2019 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R41AI145507 | Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies | 000 | 1 | NIH | 3/7/2019 | $243,282 |
| | 2019 | 2018 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R42CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 000 | 2 | NIH | 11/6/2018 | $0 |
| | 2019 | 2016 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R41HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 1 | NIH | 5/7/2019 | $0 |
| | 2019 | 2016 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R41CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 001 | 1 | NIH | 3/11/2019 | $0 |
| | 2019 | 2016 | 7 HILLS PHARMA LLC | 8285 EL RIO STE 130 | HOUSTON | TX | 77054-4654 | HARRIS | USA | R41CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 000 | 1 | NIH | 3/1/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $999,501 ) |
| | 2018 | 2018 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R42CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 001 | 2 | NIH | 9/5/2018 | $1,400 |
| | 2018 | 2018 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R42CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 000 | 2 | NIH | 4/9/2018 | $998,101 |
| | 2018 | 2016 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R41HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 1 | NIH | 3/15/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $609,636 ) |
| | 2016 | 2016 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R41CA203456 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | 000 | 1 | NIH | 6/6/2016 | $313,705 |
| | 2016 | 2016 | 7 HILLS PHARMA LLC | 2126 SHERIDAN ST | HOUSTON | TX | 77030-2108 | HARRIS | USA | R41HL129612 | A small molecule integrin activator to enhance cord blood transplant | 000 | 1 | NIH | 8/27/2016 | $295,931 |
|
|
